Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

EPO grants patent to Seegene DPO technology

The European Patent Office (EPO) has granted a patent to Seegene's Dual Priming Oligonucleotide (DPO) technology.

Seegene multiplex molecular diagnostics (M-MoDx) assays’ which are based on DPO technology can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.

The tests are used to detect infectious diseases like respiratory diseases, sexually transmitted infections, tuberculosis and also used in oncology diagnostics, pharmacogenetics tests and prognostic genetic tests.

Seegene CEO Jong-Yoon Chun said DPO enables tests to dentify and differentiate infectious agents, as well as their resistance profile, at the same time, in a single test and in a single tube.